Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New therapeutic agents for hypertension

J L Reid1

  • 1Department of Medicine and Therapeutics, University of Glasgow, UK.

British Journal of Clinical Pharmacology
|July 1, 1996
PubMed
Summary

New hypertension treatments, including angiotensin receptor antagonists (ARA) and imidazoline agonists, offer alternatives for patients unresponsive to traditional drugs. These agents may also benefit heart failure management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995
Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995
Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995
Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Internal Medicine

Background:

  • Hypertension management has evolved over 40 years with various therapeutic strategies.
  • Despite available safe and effective drugs, many patients struggle with long-term adherence due to efficacy or side effects.
  • The limitations of current treatments necessitate the development of novel antihypertensive strategies.

Purpose of the Study:

  • To review recent advancements in antihypertensive therapies.
  • To explore the potential benefits and limitations of novel drug classes.
  • To assess the implications of new treatments for patients with co-existing heart failure.

Main Methods:

  • Review of recent developments in antihypertensive drug discovery.
  • Comparative analysis of angiotensin (AT1) receptor antagonists (ARA) and imidazoline receptor agonists.
  • Evaluation of potential therapeutic applications in hypertension and heart failure.

Main Results:

  • Angiotensin (AT1) receptor antagonists (ARA) offer angiotensin II blockade without bradykinin-related side effects like cough, unlike angiotensin converting enzyme (ACE) inhibitors.
  • Imidazoline receptor agonists present potential for centrally acting antihypertensives with reduced sedation and dry mouth.
  • Both ARA and imidazoline-preferring substances show promise for favorable hemodynamic profiles in heart failure patients.

Conclusions:

  • Orally active ARA represent a significant advancement, mitigating side effects associated with ACE inhibitors.
  • Imidazoline receptor agonists require further clinical validation for long-term efficacy and tolerability.
  • Novel antihypertensive agents like ARA and imidazoline agonists may offer new therapeutic avenues for managing hypertension and heart failure.

Related Experiment Videos